Literature DB >> 7247166

Clindamycin therapy for toxoplasmosis.

J G Ferguson.   

Abstract

Clindamycin hydrochloride hydrate (Cleocin), a semisynthetic antibiotic shown experimentally to be effective in ocular toxoplasmosis in the rabbit, was used in the treatment of four patients with active retinochoroiditis secondary to toxoplasmosis. The drug was administered subjunctivally on alternate days for 30 days. Both subjective and objective evidence indicated beneficial results in these patients during the first 30 days. One of the four did not respond during the first 30 days but did respond during an extended period. One of those who responded initially had exacerbations when the drug was stopped and required treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7247166

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  6 in total

1.  Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

Authors:  M G Davidson; M R Lappin; J R Rottman; M B Tompkins; R V English; A T Bruce; J Jayawickrama
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.

Authors:  Nader Baharivand; Ali Mahdavifard; Rohollah Fadaei Fouladi
Journal:  Int Ophthalmol       Date:  2012-09-28       Impact factor: 2.031

Review 3.  Ocular involvement in toxoplasmosis.

Authors:  A Rothova
Journal:  Br J Ophthalmol       Date:  1993-06       Impact factor: 4.638

4.  Safety of intravitreal clindamycin in albino rabbit eyes.

Authors:  Zohar Habot-Wilner; Orit Mazza; Jonathan Shahar; Amir Massarweh; Irit Mann; Anat Loewenstein; Ido Perlman
Journal:  Doc Ophthalmol       Date:  2017-07-25       Impact factor: 2.379

5.  Therapy of ocular toxoplasmosis.

Authors:  A Rothova; H J Buitenhuis; C Meenken; G S Baarsma; T N Boen-Tan; P T de Jong; C M Schweitzer; Z Timmerman; J de Vries; M J Zaal
Journal:  Int Ophthalmol       Date:  1989-12       Impact factor: 2.031

Review 6.  Current treatment of toxoplasma retinochoroiditis: an evidence-based review.

Authors:  Meredith Harrell; Petros E Carvounis
Journal:  J Ophthalmol       Date:  2014-08-13       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.